Latest Updates

Board declares interim dividend of Rs 1.50 per equity share of Rs 5 each

The studies may provide the first definitive data on a Tau-based approach to disease-modifying and preventative treatment of…

Construction of new production facility to start in early 2013 and expected to be fully operational by the end of 2016

Synribo blocks certain proteins that promote the development of cancerous cells

Net profit for Q2 was Rs 1567.52million as compared to Rs 782.75 million for the previous quarter

Revenues from the global generics segment primarily driven by North America, India and other emerging markets

Will offer the seamless contract development and manufacture of antibody drug conjugates

The patent is valid till February 2026

Year-to-date sales and net income goes down

Receives US FDA approval